Du är här


CellaVision AB: CellaVision strengthens its product portfolio with two new products

This information was released for public disclosure on 2014-04-16 at 13.00 pm.

CellaVision announced today the launch of two new products. CellaVision®
DM9600, a replacement for CellaVision®DM96 for use in large laboratories, and
CellaVision® Advanced RBC Application, a unique software application for
advanced analysis of red blood cells.
The target market for CellaVision DM9600 and CellaVision Advanced RBC
Application is clinical laboratories that handle large testing volumes and
require a large capacity. With these products, CellaVision continues to lead
the way in their field of technology, and further strengthen its position in
the global market for hematology.

"The development of a replacement for our most successful analyzer, the
CellaVision DM96, has been finalized and we are proud to introduce a new
instrument that is based on the same patented hardware platform as our other
two analyzers". The CellaVision Advanced RBC Application offers future and
existing customers unique opportunities to assess red blood cells based on
shape, size and color, an important analysis for anemia and other disorders
"says Yvonne Mårtensson, CEO of CellaVision.

On July 1 the CellaVision DM9600 becomes commercially available in both Europe
and the U.S., with the CellaVision Advanced RBC Application initially
available in Europe only. Both products will be sold by the company's global
distributor network. CellaVision will apply for the necessary approvals to
sell it in other markets. The official market introduction will take place at
the ISLH Congress in The Hague, Netherlands, on 15-17 May 2014. Customers can
rely on continued provision of service and support for the discontinued
CellaVision DM96 analyzer according to CellaVision's End-of-Life Policy.
For more information, please contact:

Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 0708 33 77 82 | E-mail:yvonne.martensson@cellavision.com
CellaVision - leading the way in digital cell morphology

CellaVision is an innovative, global medical technology company that develops
and sells its own leading product concept for routine analysis of blood and
other body fluids in health care services. The concept rationalizes manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. CellaVision's product portfolio
consists of analyzers, applications, software, and consumables. In 2013 sales
were SEK 180 million and sales continue to increase, with a growth target of
at least 15 % per year over an economic cycle. CellaVision's registered
office is in Lund and the company has subsidiaries in the USA, Canada and
Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read
more atwww.cellavision.com


The information in this interim report is disclosed by CellaVision AB (publ)
pursuant to the Securities Market Act and/or the Financial Instruments
Trading Act. The information was released for public disclosure on 2014-04-16
at 13.00 pm.

Press release as PDF


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.